Brokerages Set CRISPR Therapeutics AG (NASDAQ:CRSP) PT at $71.50

CRISPR Therapeutics AG (NASDAQ:CRSP) has received a consensus rating of “Hold” from the nineteen brokerages that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and ten have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $71.50.

Several equities research analysts recently weighed in on CRSP shares. HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, September 23rd. Piper Sandler reissued an “overweight” rating and issued a $105.00 target price on shares of CRISPR Therapeutics in a report on Friday, June 27th. Zacks Research upgraded CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Royal Bank Of Canada increased their price objective on CRISPR Therapeutics from $38.00 to $42.00 and gave the company a “sector perform” rating in a research report on Tuesday, August 5th. Finally, Barclays boosted their target price on CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $67.74 on Monday. The business has a fifty day moving average price of $57.69 and a 200-day moving average price of $47.85. The company has a market capitalization of $6.16 billion, a PE ratio of -12.48 and a beta of 1.84. CRISPR Therapeutics has a 1-year low of $30.04 and a 1-year high of $73.95.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.18. The company had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. CRISPR Therapeutics’s revenue was up 72.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.49) EPS. On average, sell-side analysts anticipate that CRISPR Therapeutics will post -5.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Simeon George bought 989,812 shares of the company’s stock in a transaction that occurred on Wednesday, July 16th. The shares were bought at an average price of $52.03 per share, for a total transaction of $51,499,918.36. Following the completion of the acquisition, the director owned 1,730,179 shares of the company’s stock, valued at $90,021,213.37. This trade represents a 133.69% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CRSP. ARK Investment Management LLC grew its holdings in shares of CRISPR Therapeutics by 13.3% in the first quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company’s stock worth $345,929,000 after acquiring an additional 1,192,336 shares during the period. B & T Capital Management DBA Alpha Capital Management bought a new stake in shares of CRISPR Therapeutics during the 1st quarter valued at about $416,000. Cambridge Investment Research Advisors Inc. grew its stake in shares of CRISPR Therapeutics by 14.3% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 39,189 shares of the company’s stock valued at $1,334,000 after purchasing an additional 4,914 shares during the period. Green Alpha Advisors LLC increased its position in shares of CRISPR Therapeutics by 132.9% during the 1st quarter. Green Alpha Advisors LLC now owns 57,361 shares of the company’s stock valued at $1,952,000 after purchasing an additional 32,732 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of CRISPR Therapeutics by 1.9% in the 1st quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company’s stock worth $60,223,000 after purchasing an additional 33,711 shares during the period. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.